Clinical Trial Update: Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 safety and tolerability study of SNS01-T in relapsed or refractory B-cell malignancies sponsored by Senesco Technologies. The trial encompasses multip…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma
• Plasma Cell Leukemia

Drugs mentioned

• SNS01-T

Snippet

Sponsor: Senesco Technologies, Inc. | Conditions: Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1, Phase 2 | Status: UNKNOWN